myelodysplastic syndromes (MDS) | Aplastic Anemia & MDS International Foundation

myelodysplastic syndromes (MDS)

RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis

Author(s): 
Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ
Primary Author: 
Zeidan AM
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
Jun 2019

Most patients with lower risk

Bone Marrow Diseases: 

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Author(s): 
Drusbosky LM, Singh NK, Hawkins KE, Salan C, Turcotte M, Wise EA, Meacham A, Vijay V, Anderson GG, Kim CC, Radhakrishnan S, Ullal Y, Talawdekar A, Sikora H, Nair P, Khanna-Gupta A, Abbasi T, Vali S, Guha S, Farhadfar N, Murthy HS
Primary Author: 
Drusbosky LM
Journal Title: 
Blood Advances
Original Publication Date: 
Jun 2019

Patients with

Bone Marrow Diseases: 

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Author(s): 
Garcia-Manero G, Roboz G, Walsh K, Kantarjian H, Ritchie E, Kropf P, O'Connell C, Tibes R, Lunin S, Rosenblat T, Yee K, Stock W, Griffiths E, Mace J, Podoltsev N, Berdeja J, Jabbour E, Issa JJ, Hao Y, Keer HN, Azab M, Savona MR
Primary Author: 
Garcia-Manero G
Journal Title: 
The Lancet Haematology
Original Publication Date: 
Jun 2019

BACKGROUND:

Bone Marrow Diseases: 

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes

Author(s): 
Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC
Primary Author: 
Sekeres MA
Journal Title: 
Leukemia & Lymphoma
Original Publication Date: 
May 2019

Bone Marrow Diseases: 

Management of myelodysplastic syndromes after failure of response to hypomethylating agents

Author(s): 
Gil-Perez A, Montalban-Bravo G
Primary Author: 
Gil-Perez A
Journal Title: 
Therapeutic Advances in Hematology
Original Publication Date: 
May 2019

Hypomethylating agents (HMAs) are the standard of care for patients with myelodysplastic syndrome (MDS). However, only around 50% of patients respond to these agents, and responses tend to be transient, with loss of response frequently happening within 2 years and being associated with very poor prognosis and limited therapeutic options. Identification of patients who will respond to HMAs is challenging. Mechanisms underlying resistance to HMAs are not clear yet.

Bone Marrow Diseases: 

2019 Patient & Family Conference (Rockville, Maryland)

Thank you for attending the 2019 Patient & Family Conference in Rockville, Maryland. 

Event Date: 
Sat, 05/18/2019 - 7:30am
Conference Event Type: